/PRNewswire/ Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor –.
/PRNewswire/ Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor –.
/PRNewswire/ ThoughtWorld is now at your fingertips. The social sharing site that features interactive virtual graphics and anonymous posting has landed on.
/PRNewswire/ ThoughtWorld is now at your fingertips. The social sharing site that features interactive virtual graphics and anonymous posting has landed on.